A Heart Valve Designed to Grow with Children

Children born with certain heart conditions may face multiple surgeries as they grow. One reason is surprisingly simple: replacement heart valves generally cannot grow with the child.

On October 1, 2026, the U.S. Food and Drug Administration (FDA) approved a device designed to address that challenge: the AUTUS Size-Adjustable Valve, developed by Edwards Lifesciences (PMA P260007). The new valve represents an important advance in pediatric heart valve design. But its approval also illustrates an important aspect of medical device regulation: innovative technology can offer promising new possibilities while important questions about its long-term performance remain unanswered.

Why children may need repeated heart valve surgeries

The pulmonary valve controls blood flow from the heart to the lungs. In children with certain congenital heart conditions, the valve may become narrowed, allowing too little blood to pass through, or may leak, allowing blood to flow backward.

When the problem becomes sufficiently severe, the child may require pulmonary valve replacement. However, conventional replacement valves have a fixed size. As children grow, a valve that initially functions well may eventually become too small or otherwise require replacement. For some families, this means additional open-heart surgeries during childhood.

How the AUTUS valve works

The AUTUS valve takes a different approach. It uses synthetic valve leaflets mounted within a stainless-steel frame that can be expanded using a balloon.

The valve is surgically implanted and sized to the child’s anatomy. If the child later needs a larger valve, physicians may be able to expand the implanted device through a catheter-based procedure rather than performing another open-heart operation. The valve has a functional internal diameter range of 12.7 to 22 millimeters.

FDA approved AUTUS for pediatric patients weighing at least 10 kilograms who require pulmonary valve replacement for specified conditions involving narrowing, leakage, or both. The technology offers the possibility of accommodating a child’s growth while reducing the need for repeated surgical valve replacement.

What did the clinical study demonstrate?

FDA reviewed clinical evidence involving 62 children who received the AUTUS valve. The study evaluated procedural safety and valve performance, including blood flow through the valve and complications following implantation.

The initial findings supported FDA’s decision to approve the device for its specified use. However, an important distinction appears in the FDA-approved instructions for use.

The safety and effectiveness of post-implantation expansion not established

At the time of FDA’s review, only two children in the clinical study had undergone post-implant expansion. There was also no clinical experience involving more than one expansion procedure in the same patient. In other words, the device is designed to accommodate growth, but the long-term clinical benefits of that capability still need to be demonstrated.

The clinical evidence also identified findings requiring continued monitoring, including valve-frame fractures in three patients and reduced leaflet movement in two patients. The reported findings had not produced symptoms or impaired valve function at the time described in the patient information. These findings do not negate the approval, but they reinforce the importance of long-term surveillance.

FDA requires continued studies of the device

FDA’s approval includes substantial post-approval requirements. Edwards Lifesciences must continue monitoring the original clinical study population for up to 10 years. The company must also conduct a new prospective study involving at least 150 patients, with follow-up extending through 10 years after implantation.

Those studies will evaluate valve performance, durability, complications, and the safety and effectiveness of expanding the valve after implantation. FDA also requires additional nonclinical testing of the valve-frame material.

These requirements are particularly important for a device intended for children, whose treatment needs may extend over many years.

Innovation and evidence must advance together

The AUTUS approval illustrates both the promise and the challenges of developing medical devices for pediatric patients. The technology addresses a genuine clinical problem: children grow, but conventional replacement valves do not.

Its expandable design may eventually reduce the need for repeated open-heart surgery, offering important potential benefits for patients and families. However, those benefits cannot be assumed solely from the device’s design or its initial FDA approval. The evidence must continue to develop as patients are followed over time.

MDP regulatory intelligence perspective

The AUTUS Size-Adjustable Valve is an important example of when medical device innovation, clinical evidence, and regulatory oversight intersect.

FDA’s approval authorizes the device for a defined pediatric population based on the evidence submitted. At the same time, its labeling acknowledges limitations in the available clinical experience, and its approval conditions require continued evaluation. For regulatory professionals, the distinction is essential.

Technological capability not the same as a demonstrated long-term benefit

The AUTUS approval demonstrates how FDA’s premarket approval process can support access to innovative medical technologies while requiring manufacturers to continue gathering evidence about their performance and safety.

For children and families facing repeated heart valve procedures, the technology offers a promising new option. Whether it can substantially reduce the need for additional surgeries over a patient’s lifetime remains an important question for the years ahead.